204-IL) and 10 µg/mL Goat Anti-Human IFN-gamma Antigen Affinity-purified Polyclonal Antibody (Catalog #
AF-285-NA) for three days followed by a 3 hour incubation with monensin were stained with Mouse Anti-Human APRIL/TNFSF13 Monoclonal Antibody (Catalog # MAB8843) followed by Phycoerythrin-conjugated Anti-Mouse IgG Secondary Antibody (Catalog #
F0102B) and Mouse Anti-Human CD4 APC-conjugated Monoclonal Antibody (Catalog #
FAB3791A). Quadrant markers were set based on control antibody staining (Catalog #
MAB004). To facilitate intracellular staining, cells were fixed with paraformaldehyde and permeabilized with saponin." class="big_lightbox">

204-IL) and 10 µg/mL Goat Anti-Human IFN-gamma Antigen Affinity-purified Polyclonal Antibody (Catalog #
AF-285-NA) for three days followed by a 3 hour incubation with monensin were stained with Mouse Anti-Human APRIL/TNFSF13 Monoclonal Antibody (Catalog # MAB8843) followed by Phycoerythrin-conjugated Anti-Mouse IgG Secondary Antibody (Catalog #
F0102B) and Mouse Anti-Human CD4 APC-conjugated Monoclonal Antibody (Catalog #
FAB3791A). Quadrant markers were set based on control antibody staining (Catalog #
MAB004). To facilitate intracellular staining, cells were fixed with paraformaldehyde and permeabilized with saponin." alt="Human peripheral blood monocytes stimulated with 5 ng/mL Recombinant Human IL-4 (Catalog #
204-IL) and 10 µg/mL Goat Anti-Human IFN-gamma Antigen Affinity-purified Polyclonal Antibody (Catalog #
AF-285-NA) for three days followed by a 3 hour incubation with monensin were stained with Mouse Anti-Human APRIL/TNFSF13 Monoclonal Antibody (Catalog # MAB8843) followed by Phycoerythrin-conjugated Anti-Mouse IgG Secondary Antibody (Catalog #
F0102B) and Mouse Anti-Human CD4 APC-conjugated Monoclonal Antibody (Catalog #
FAB3791A). Quadrant markers were set based on control antibody staining (Catalog #
MAB004). To facilitate intracellular staining, cells were fixed with paraformaldehyde and permeabilized with saponin." class="big_thumb" />